In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine)

European Journal of Pharmacology

Volumn 473, Issue 1, 2003, Pages 35-40

  Anderson, Jeffery J ^a   Bradbury, Margaret J ^a   Giracello, Darlene R ^a   Chapman, Deborah F ^a   Holtz, Greg ^a   Roppe, Jeffrey ^a   King, Chris ^a   Cosford, Nicholas D P ^a   Varney, Mark A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Metabotropic glutamate receptor; mGlu5; Occupancy; Receptor binding

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 METHOXY 5 (PYRIDIN 2 YLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; RADIOLIGAND; RECEPTOR SUBTYPE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DEGRADATION; DRUG RECEPTOR BINDING; FOREBRAIN; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RECEPTOR OCCUPANCY; SPECIES COMPARISON; SPECIES DIFFERENCE; WILD TYPE;

EID: 0038825269     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01935-6     Document Type: Article

References (24)

1. 3H]methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 303:2002;1044-1051.
2. 3H]Ro 15-1788 binding reflect selectivity for alpha 1 versus alpha 2 and alpha 3 subunit-containing GABAA receptors. Neuropsychopharmacology. 20:1999;255-262.
3. Bordi F., Ugolini A. Involvement of mGluR(5) on acute nociceptive transmission. Brain Res. 871:2000;223-233.
4. Breysse N., Baunez C., Spooren W., Gasparini F., Amalric M. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J. Neurosci. 22:2002;5669-5678.
5. Brodkin J., Bradbury M., Busse C., Warren N., Bristow L.J., Varney M.A. Reduced stress-induced hyperthermia in mGluR5 knockout mice. Eur. J. Neurosci. 16:2002;2241-2244.
6. Brodkin J., Busse C., Sukoff S.J., Varney M.A. Anxiolytic-like activity of the mGluR5 antagonist MPEP a comparison with diazepam and buspirone. Pharmacol. Biochem. Behav. 73:2002;359-366.
7. Camon L., Vives P., de Vera N., Martinez E. Seizures and neuronal damage induced in the rat by activation of group I metabotropic glutamate receptors with their selective agonist 3,5-dihydroxyphenylglycine. J. Neurosci. Res. 51:1998;339-348.
8. Chapman A.G., Nanan K., Williams M., Meldrum B.S. Anticonvulsant activity of two metabotropic glutamate group I antagonists selective for the mGlu5 receptor: 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and (E)-6-methyl-2-styryl-pyridine (SIB 1893). Neuropharmacology. 39:2000;1567-1574.
9. Collins J.M. Inter-species differences in drug properties. Chem. Biol. Interact. 134:2001;237-242.
10. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 37:1997;205-237.
11. 3H]methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg. Med. Chem. Lett. 13:2003;345-348.
12. Fisher K., Coderre T.J. Comparison of nociceptive effects produced by intrathecal administration of mGluR agonists. NeuroReport. 7:1996;2743-2747.
13. 3H]M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg. Med. Chem. Lett. 12:2002;407-409.
14. Karim F., Bhave G., Gereau R.W.T. Metabotropic glutamate receptors on peripheral sensory neuron terminals as targets for the development of novel analgesics. Mol. Psychiatry. 6:2001;615-617.
15. Lu Y.M., Jia Z., Janus C., Henderson J.T., Gerlai R., Wojtowicz J.M., Roder J.C. Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17:1997;5196-5205.
16. Martinez M.N. Use of pharmacokinetics in veterinary medicine. Article II: volume, clearance, and half-life. J. Am. Vet. Med. Assoc. 213:1998;1122-1127.
17. 3H]methoxyPEPy, an mGluR5 selective radioligand. Life Sci. 73:2003;371-379.
18. Pin J.P., Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology. 34:1995;1-26.
19. Rao S., Verkman A.S. Analysis of organ physiology in transgenic mice. Am. J. Physiol. Cell Physiol. 279:2000;C1-C18.
20. Romano C., Sesma M.A., McDonald C.T., O'Malley K., Van den Pol A.N., Olney J.W. Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 355:1995;455-469.
21. Shigemoto R., Nomura S., Ohishi H., Sugihara H., Nakanishi S., Mizuno N. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163:1993;53-57.
22. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295:2000;1267-1275.
23. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132:2001;1423-1430.
24. Walker K., Bowes M., Panesar M., Davis A., Gentry C., Kesingland A., Gasparini F., Spooren W., Stoehr N., Pagano A., Flor P.J., Vranesic I., Lingenhoehl K., Johnson E.C., Varney M., Urban L., Kuhn R. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function: I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology. 40:2001;1-9.